These tumors often display discordant morphological and immunohistochemical features, harboring genetic alterations characteristic of both SCLC (e.g., TP53, RB1 loss) and NSCLC (e.g., KRAS, STK11 mutations) [113]. The gene discussed is TP53; the disease is small cell lung carcinoma.